Integra LifeSciences Holdings Corporation (IART) Analysts See $0.60 EPS

June 27, 2018 - By Ash

Investors sentiment decreased to 0.92 in 2018 Q1. Its down 0.06, from 0.98 in 2017Q4. It dived, as 21 investors sold Integra LifeSciences Holdings Corporation shares while 75 reduced holdings. 37 funds opened positions while 51 raised stakes. 69.24 million shares or 1.40% less from 70.22 million shares in 2017Q4 were reported.
Bank & Trust Of Mellon owns 726,722 shares. Fortaleza Asset holds 0.78% or 2,305 shares in its portfolio. State Street has invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Wells Fargo And Mn has 0.01% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). 253,855 were accumulated by Boston Prtn. 131,462 are owned by Manufacturers Life Ins The. Profund Advsr Ltd Liability accumulated 13,275 shares or 0.03% of the stock. Sigma Planning Corp owns 40,657 shares. Fdx Advisors Inc invested in 0.01% or 7,586 shares. Fisher Asset Mngmt Lc has 1.26M shares. Quantitative Systematic Strategies Limited Liability holds 0.06% or 4,871 shares in its portfolio. Teachers Retirement Of The State Of Kentucky holds 0.03% or 45,748 shares in its portfolio. California Employees Retirement Systems invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Putnam Investments Lc invested 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Quantitative Inv Lc reported 11,000 shares stake.

Analysts expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report $0.60 EPS on July, 25.They anticipate $0.15 EPS change or 33.33 % from last quarter’s $0.45 EPS. IART’s profit would be $50.99M giving it 27.08 P/E if the $0.60 EPS is correct. After having $0.58 EPS previously, Integra LifeSciences Holdings Corporation’s analysts see 3.45 % EPS growth. The stock decreased 0.03% or $0.02 during the last trading session, reaching $65. About 11,218 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 28.46% since June 27, 2017 and is uptrending. It has outperformed by 15.89% the S&P500.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Among 9 analysts covering Integra Lifesciences (NASDAQ:IART), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. Integra Lifesciences had 11 analyst reports since January 2, 2018 according to SRatingsIntel. The firm has “Market Perform” rating given on Tuesday, January 2 by Raymond James. Jefferies maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) rating on Wednesday, April 25. Jefferies has “Buy” rating and $7000 target. JP Morgan maintained the stock with “Neutral” rating in Wednesday, April 11 report. The stock has “Neutral” rating by Bank of America on Tuesday, January 2. The firm earned “Hold” rating on Wednesday, April 25 by Cantor Fitzgerald. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, February 28. The firm earned “Neutral” rating on Tuesday, May 22 by JP Morgan. The company was maintained on Thursday, April 26 by JP Morgan. Oppenheimer maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) on Thursday, March 29 with “Buy” rating.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $5.52 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 74.03 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

More news for Integra LifeSciences Holdings Corporation (NASDAQ:IART) were recently published by: Streetinsider.com, which released: “Evergy (EVRG) Set to Join S&P 500; Navient (NAVI) and Integra Lifesciences Holdings (IART) to Join S&P MidCap 400 …” on May 31, 2018. Seekingalpha.com‘s article titled: “Ambac Financial +4.2% on index promotion; IART, EVRG, NAVI changing places” and published on May 31, 2018 is yet another important article.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.